Soluble Fas ligand released by colon adenocarcinoma cells induces host lymphocyte apoptosis: An active mode of immune evasion in colon cancer

British Journal of Cancer

Volumn 85, Issue 7, 2001, Pages 1047-1054

  Song, E ^a,b   Chen, J ^b   Ouyang, N ^a   Su, F ^b   Wang, M ^a,b   Heemann, U ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Apoptosis; Colon neoplasms; Immune evasion; Soluble Fas ligand

Indexed keywords

FAS LIGAND;

ADULT; AGED; APOPTOSIS; ARTICLE; CELL COMMUNICATION; CLINICAL ARTICLE; COLON ADENOCARCINOMA; COLON CANCER; COLON CARCINOGENESIS; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE SYSTEM; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SECRETION;

ADENOCARCINOMA; AGED; APOPTOSIS; CELL MEMBRANE; COLONIC NEOPLASMS; FAS LIGAND PROTEIN; FEMALE; HUMANS; JURKAT CELLS; LYMPHOCYTES; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; TUMOR CELLS, CULTURED;

EID: 0035964621     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6692042     Document Type: Article

References (39)

1. Fas ligand mediates activation-induced cell death in human T lymphocytes
2. A role for CD95 ligand in preventing graft rejection
3. The Fas counterattack in vivo: Apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma
4. Expression of fas ligand by human gastric adenocarcinomas: A potential mechanism of immune escape in stomach cancer
5. Levels of soluble FasL and FasL gene expression during the development of graft-versus-host disease in DLT-treated patients
6. Soluble HLA class I, HLA class II, and Fas ligand in blood components: A possible key to explain the immunomodulatory effects of allogeneic blood transfusions
7. Fas ligand-induced apoptosis as a mechanism of immune privilege
8. Oligoclonal T cells in human cancer
9. Fas ligand is positioned in mouse uterus and placenta to prevent trafficking of activated leukocytes between the mother and the concepts
10. Elevated serum soluble Fas ligand in natural killer cell proliferative disorders
11. Cotransplantation of allogeneic islets with allogeneic testicular cell aggregates allows long-term graft survival without systemic immunosuppression
12. The role of APO-1 mediated apoptosis in the immune system
13. CD95 (APO-1/Fas)-mediated apoptosis in normal and malignant liver, colon, and hematopoietic cells
14. Fas ligand is constitutively secreted by prostate cancer cells in vitro
15. Modulations of the effector function and cytokine production of human lymphocytes by secreted factors derived from colorectal-carcinoma cells
16. Comparison of the effects of immunosuppressive factors from newly established colon carcinoma cell cultures on human lymphocyte proliferation and cytokine secretion
17. Malaria infection induces rapid elevation of the soluble Fas ligand level in serum and subsequent T lymphocytopenia: Possible factors responsible for the differences in susceptibility of two species of Macaca monkeys to Plasmodium coatneyi infection
18. Soluble fas ligand induces epithelial cell apoptosis in humans with acute lung injury (ARDS)
19. Liver dysfunction due to apoptosis in a patient with systemic lupus erythematosus
20. Soluble fas ligand in natural killer cell lymphoma
21. The fas death factor
22. The fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing fas ligand
23. Fas ligand expression in primary colon adenocarcinomas: Evidence that the fas counterattack is a prevalent mechanism of immune evasion in human colon cancer
24. Requirement of cell-cell contact in the induction of Jurkat T cell apoptosis: The membrane-anchored but not soluble form of FasL can trigger anti-CD3-induced apoptosis in Jurkat T cells
25. Increased levels of soluble fas ligand in CSF of rapidly progressive HTLV-1-associated myelopathy/tropical spastic paraparesis patients
26. An aggressive nasal lymphoma accompanied by high levels of soluble fas ligand
27. Characterization of Fas (Apo-1, CD95)-fas ligand interaction
28. Clinical significance of serum soluble Fas ligand in patients with acute self-limited and fulminant hepatitis
29. Kupffer cells of cirrhotic rat livers sensitise colon cancer cells to Fas-mediated apoptosis
30. Soluble Fas ligand expression in the ocular fluids of uveitis patients
31. Increased levels of soluble Fas receptor and Fas ligand in the cerebrospinal fluid of HIV-infected patients
32. Lymphocyte apoptosis induced by CD95 (Apo-1/CD95) ligand: Implications for tumor immune escape
33. CD95 ligand (FasL)-induced apoptosis is necessary for corneal allograft survival
34. Increased serum soluble Fas ligand in hyperthyroid Graves's disease
35. Fas ligand in human serum
36. Downregulation of Fas ligand by shedding
37. Preoperative lymphocyte counts in peripheral blood in patients with colorectal neoplasms: A correlation with tumor type, Kukes' classification, site of primary tumor, and five-year survival rate in 1000 patients
38. Levels of soluble fas ligand in myocarditis
39. Fas ligand expression in esophageal carcinomas and their lymph-node metastases